{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T01:57:10Z","timestamp":1795053430300,"version":"4.10.2"},"reference-count":92,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010875","name":"Amgen Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010875","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013739","name":"Pfizer Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014554","name":"Janssen Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016040","name":"Takeda Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","award":["SDR 18-151"],"award-info":[{"award-number":["SDR 18-151"]}],"id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015631","name":"Merck Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015631","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1053\/j.gastro.2021.12.247","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:41:39Z","timestamp":1645058499000},"page":"1334-1342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":330,"title":["AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review"],"prefix":"10.1053","volume":"162","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4366-9076","authenticated-orcid":false,"given":"Laura E.","family":"Targownik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer D.","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2021.12.247_bib1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1177\/1756283X16650156","article-title":"Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study","volume":"9","author":"Pottegard","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1053\/j.gastro.2021.12.247_bib2","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820913743","article-title":"Long-term use of proton-pump inhibitors: whole-of-population patterns in Australia 2013-2016","volume":"13","author":"Daniels","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1053\/j.gastro.2021.12.247_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208461","article-title":"A\u00a0cross-sectional study of national outpatient gastric acid suppressant prescribing in the United States between 2009 and 2015","volume":"13","author":"Bustillos","year":"2018","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2021.12.247_bib4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00228-019-02810-1","article-title":"Use of proton pump inhibitors in adults in France: a nationwide drug utilization study","volume":"76","author":"Lassalle","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1053\/j.gastro.2021.12.247_bib5","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/pds.4043","article-title":"Proton pump inhibitor prescribing patterns in the UK: a primary care database study","volume":"25","author":"Othman","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1053\/j.gastro.2021.12.247_bib6","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1053\/gast.1997.v112.pm9178669","article-title":"Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis","volume":"112","author":"Chiba","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.12.247_bib7","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM199803123381104","article-title":"A\u00a0comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group","volume":"338","author":"Yeomans","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.12.247_bib8","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJM199803123381105","article-title":"Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group","volume":"338","author":"Hawkey","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.12.247_bib9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1056\/NEJM198901123200201","article-title":"Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer","volume":"320","author":"Walan","year":"1989","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.12.247_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056060","article-title":"Proton pump inhibitor use in the U.S. ambulatory setting, 2002-2009","volume":"8","author":"Rotman","year":"2013","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2021.12.247_bib12","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1111\/jgs.13702","article-title":"American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults","volume":"63","year":"2015","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1053\/j.gastro.2021.12.247_bib14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/ajg.2013.421","article-title":"Consumer use of over-the-counter proton pump inhibitors in patients with gastroesophageal reflux disease","volume":"109","author":"Sheikh","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.12.247_bib15","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40265-019-01110-3","article-title":"The clinician's guide to proton pump inhibitor related adverse events","volume":"79","author":"Elias","year":"2019","journal-title":"Drugs"},{"key":"10.1053\/j.gastro.2021.12.247_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/j.gastro.2017.04.047","article-title":"Complications of proton pump inhibitor therapy","volume":"153","author":"Vaezi","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.12.247_bib17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1503\/cmaj.071330","article-title":"Use of proton pump inhibitors and risk of osteoporosis-related fractures","volume":"179","author":"Targownik","year":"2008","journal-title":"CMAJ"},{"key":"10.1053\/j.gastro.2021.12.247_bib18","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamaneurol.2015.4791","article-title":"Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis","volume":"73","author":"Gomm","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1053\/j.gastro.2021.12.247_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015735","article-title":"Risk of death among users of proton pump inhibitors: a longitudinal observational cohort study of United States veterans","volume":"7","author":"Xie","year":"2017","journal-title":"BMJ Open"},{"key":"10.1053\/j.gastro.2021.12.247_bib20","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1053\/j.gastro.2017.05.046","article-title":"Association between proton pump inhibitor use and risk of progression of chronic kidney disease","volume":"153","author":"Klatte","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.12.247_bib21","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.14309\/ajg.0000000000000798","article-title":"Increased risk of COVID-19 among users of proton pump inhibitors","volume":"115","author":"Almario","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.12.247_bib22","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1053\/j.gastro.2019.10.023","article-title":"Interpreting reported risks associated with use of proton pump inhibitors: residual confounding in a 10-year analysis of national ambulatory data","volume":"158","author":"Ma","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.12.247_bib23","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2019.05.056","article-title":"Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.12.247_bib24","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/S0140-6736(07)60749-1","article-title":"Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial","volume":"369","author":"Chan","year":"2007","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2021.12.247_bib25","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1111\/jgs.16136","article-title":"Advancing the science of deprescribing: a novel comprehensive conceptual framework","volume":"67","author":"Linsky","year":"2019","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1053\/j.gastro.2021.12.247_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-041529","article-title":"Trends in acid suppressant drug prescriptions in primary care in the UK: a population-based cross-sectional study","volume":"10","author":"Abrahami","year":"2020","journal-title":"BMJ Open"},{"key":"10.1053\/j.gastro.2021.12.247_bib27","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.sapharm.2018.08.010","article-title":"Deprescribing guidelines: an international symposium on development, implementation, research and health professional education","volume":"15","author":"Farrell","year":"2019","journal-title":"Res Social Adm Pharm"},{"key":"10.1053\/j.gastro.2021.12.247_bib28","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/MAJ.0b013e31829f87d5","article-title":"Potential costs of inappropriate use of proton pump inhibitors","volume":"347","author":"Ladd","year":"2014","journal-title":"Am J Med Sci"},{"key":"10.1053\/j.gastro.2021.12.247_bib29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/1756283X12437358","article-title":"Overutilization of proton-pump inhibitors: what the clinician needs to know","volume":"5","author":"Heidelbaugh","year":"2012","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1053\/j.gastro.2021.12.247_bib30","first-page":"e228","article-title":"Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting","volume":"16","author":"Heidelbaugh","year":"2010","journal-title":"Am J Manag Care"},{"key":"10.1053\/j.gastro.2021.12.247_bib31","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jamda.2007.07.001","article-title":"Use of proton pump inhibitors and other acid suppressive medications in newly admitted nursing facility patients","volume":"8","author":"Glew","year":"2007","journal-title":"J\u00a0Am Med Dir Assoc"},{"key":"10.1053\/j.gastro.2021.12.247_bib32","first-page":"CD002095","article-title":"Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease","volume":"5","author":"Sigterman","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1053\/j.gastro.2021.12.247_bib33","article-title":"Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease","author":"Donnellan","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.gastro.2021.12.247_bib34","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1016\/j.mayocp.2020.07.038","article-title":"Prevalence and risk factors for inappropriate continuation of proton pump inhibitors after discharge from the intensive care unit","volume":"96","author":"Blackett","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.gastro.2021.12.247_bib35","article-title":"Use of proton pump inhibitors to treat persistent throat symptoms: multicentre, double blind, randomised, placebo controlled trial","volume":"372","author":"O\u2019Hara","year":"2021","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2021.12.247_bib36","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1572-0241.2007.01106.x","article-title":"The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use","volume":"102","author":"Targownik","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.12.247_bib37","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1001\/jama.294.23.2989","article-title":"Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease","volume":"294","author":"Dial","year":"2005","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2021.12.247_bib38","doi-asserted-by":"crossref","DOI":"10.1001\/jama.292.16.1955","article-title":"Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs","volume":"292","author":"Laheij","year":"2004","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2021.12.247_bib39","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","article-title":"Long-term proton pump inhibitor therapy and risk of hip fracture","volume":"296","author":"Yang","year":"2006","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2021.12.247_bib40","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/j.1365-2036.2012.05047.x","article-title":"Randomised clinical trial: high-dose vs. standard-dose proton pump inhibitors for the prevention of recurrent haemorrhage after combined endoscopic haemostasis of bleeding peptic ulcers","volume":"35","author":"Chen","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.12.247_bib41","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/ajg.2015.322","article-title":"ACG Clinical Guideline: diagnosis and management of Barrett's esophagus","volume":"111","author":"Shaheen","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.12.247_bib42","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1053\/j.gastro.2008.08.045","article-title":"American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease","volume":"135","author":"Kahrilas","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.12.247_bib43","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2036.2006.02762.x","article-title":"Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions","volume":"23","author":"Metz","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.12.247_bib44","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1111\/j.1572-0241.2007.01509.x","article-title":"Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion","volume":"102","author":"Metz","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.12.247_bib45","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1111\/j.1572-0241.2003.07665.x","article-title":"Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs","volume":"98","author":"Inadomi","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2021.12.247_bib46","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000151249","article-title":"Epidemiology of non-erosive reflux disease","volume":"78","author":"El-Serag","year":"2008","journal-title":"Digestion"},{"key":"10.1053\/j.gastro.2021.12.247_bib47","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1136\/gut.2007.145177","article-title":"Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study","volume":"57","author":"Zagari","year":"2008","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.12.247_bib48","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1046\/j.1365-2036.1997.00167.x","article-title":"Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials","volume":"11","author":"Carlsson","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.12.247_bib49","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/j.1572-0241.2006.00631.x","article-title":"Detection of Barrett's esophagus after endoscopic healing of erosive esophagitis","volume":"101","author":"Hanna","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.12.247_bib50","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1046\/j.1365-2036.2001.01024.x","article-title":"The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety","volume":"15","author":"Vakil","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.12.247_bib51","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJM199903183401101","article-title":"Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma","volume":"340","author":"Lagergren","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.12.247_bib52","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0140-6736(18)31388-6","article-title":"Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial","volume":"392","author":"Jankowski","year":"2018","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2021.12.247_bib53","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1136\/gutjnl-2013-305997","article-title":"Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis","volume":"63","author":"Singh","year":"2014","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.12.247_bib54","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1053\/j.gastro.2020.02.038","article-title":"AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.12.247_bib55","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1136\/gutjnl-2015-310991","article-title":"Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis","volume":"65","author":"Molina-Infante","year":"2016","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.12.247_bib56","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cgh.2015.07.041","article-title":"Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis","volume":"14","author":"Lucendo","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.12.247_bib57","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.cgh.2006.05.026","article-title":"Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis","volume":"4","author":"Kagalwalla","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.12.247_bib58","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1053\/j.gastro.2012.03.001","article-title":"Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors","volume":"142","author":"Gonsalves","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.12.247_bib59","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1053\/j.gastro.2017.06.067","article-title":"Epidemiology and natural history of eosinophilic esophagitis","volume":"154","author":"Dellon","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.12.247_bib60","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/thoraxjnl-2018-212102","article-title":"Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis","volume":"74","author":"Dutta","year":"2019","journal-title":"Thorax"},{"key":"10.1053\/j.gastro.2021.12.247_bib61","doi-asserted-by":"crossref","first-page":"444","DOI":"10.5056\/jnm15192","article-title":"Protective effect of proton pump inhibitor for survival in patients with gastroesophageal reflux disease and idiopathic pulmonary fibrosis","volume":"22","author":"Lee","year":"2016","journal-title":"J\u00a0Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2021.12.247_bib62","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/qjmed\/hcw115","article-title":"Proton pump inhibitors in IPF: beyond mere suppression of gastric acidity","volume":"109","author":"Ghebre","year":"2016","journal-title":"QJM"},{"key":"10.1053\/j.gastro.2021.12.247_bib63","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1572-0241.2006.01062.x","article-title":"Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants","volume":"102","author":"Lanas","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.12.247_bib64","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1136\/gut.2005.080754","article-title":"Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations","volume":"55","author":"Lanas","year":"2006","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.12.247_bib65","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1075-122X.2006.00255.x","article-title":"Hemangioma of the breast: clinical, mammographic, and ultrasound features","volume":"12","author":"Adwani","year":"2006","journal-title":"Breast J"},{"key":"10.1053\/j.gastro.2021.12.247_bib66","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0016-5085(98)70307-5","article-title":"Intractable upper gastrointestinal ulceration due to aspirin in patients who have undergone surgery for peptic ulcer","volume":"114","author":"Hirschowitz","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.12.247_bib67","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1053\/gast.1997.v112.pm9041228","article-title":"Evidence of aspirin use in both upper and lower gastrointestinal perforation","volume":"112","author":"Lanas","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.12.247_bib68","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa042087","article-title":"Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding","volume":"352","author":"Chan","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.12.247_bib69","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-2036.2006.02829.x","article-title":"The prevalence of risk factors for gastrointestinal complications and use of gastroprotection among persons hospitalized for cardiovascular disease","volume":"23","author":"Targownik","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.12.247_bib70","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1053\/j.gastro.2008.01.010","article-title":"The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs","volume":"134","author":"Targownik","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.12.247_bib71","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.12.247_bib72","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/jama.2018.17242","article-title":"Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding","volume":"320","author":"Ray","year":"2018","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2021.12.247_bib73","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1161\/CIR.0b013e318202f701","volume":"122","author":"Abraham","year":"2010","journal-title":"Circulation"},{"key":"10.1053\/j.gastro.2021.12.247_bib74","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1053\/j.gastro.2021.12.247_bib75","first-page":"728","article-title":"Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications","volume":"104","author":"Lanza","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.12.247_bib76","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","volume":"77","author":"Kumbhani","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1053\/j.gastro.2021.12.247_bib77","doi-asserted-by":"crossref","first-page":"805","DOI":"10.7326\/M19-1795","article-title":"Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the International Consensus Group","volume":"171","author":"Barkun","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2021.12.247_bib78","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7326\/0003-4819-152-2-201001190-00009","article-title":"International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding","volume":"152","author":"Barkun","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2021.12.247_bib79","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST Guideline and Expert Panel Report","volume":"154","author":"Lip","year":"2018","journal-title":"CHEST"},{"key":"10.1053\/j.gastro.2021.12.247_bib80","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2036.2004.02271.x","article-title":"Rebound acid hypersecretion after long-term inhibition of gastric acid secretion","volume":"21","author":"Fossmark","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.12.247_bib81","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/gut.39.5.649","article-title":"Marked increase in gastric acid secretory capacity after omeprazole treatment","volume":"39","author":"Waldum","year":"1996","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.12.247_bib82","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2036.1999.00466.x","article-title":"Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study","volume":"13","author":"Sanduleanu","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.12.247_bib83","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/MCG.0000000000001200","article-title":"Predictors of gastrin elevation following proton pump inhibitor therapy","volume":"54","author":"Helgad\u00f3ttir","year":"2020","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1053\/j.gastro.2021.12.247_bib84","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/j.gastro.2009.03.058","article-title":"Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy","volume":"137","author":"Reimer","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.12.247_bib85","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/ajg.2010.81","article-title":"Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial","volume":"105","author":"Niklasson","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.12.247_bib86","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1053\/gast.2001.28649","article-title":"Step-down management of gastroesophageal reflux disease","volume":"121","author":"Inadomi","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.12.247_bib87","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2036.2007.03381.x","article-title":"Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken 'on-demand","volume":"26","author":"Pace","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.12.247_bib88","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1365-2036.2006.03084.x","article-title":"Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial","volume":"24","author":"Bj\u00f6rnsson","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.12.247_bib89","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association","volume":"152","author":"Freedberg","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.12.247_bib90","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/ndt\/gfw470","article-title":"The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis","volume":"33","author":"Nochaiwong","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.gastro.2021.12.247_bib91","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1038\/ajg.2013.333","article-title":"Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients","volume":"108","author":"Freedberg","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.12.247_bib92","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/ajg.2014.372","article-title":"The importance of accounting for immortal time bias in pharmacoepidemiologic analyses","volume":"110","author":"Targownik","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.12.247_bib93","doi-asserted-by":"crossref","first-page":"244","DOI":"10.14309\/ajg.0000000000000061","article-title":"Patients' perceptions of proton pump inhibitor risks and attempts at discontinuation: a national survey","volume":"114","author":"Kurlander","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.12.247_bib94","doi-asserted-by":"crossref","first-page":"689","DOI":"10.14309\/ajg.0000000000000558","article-title":"Physicians' perceptions of proton pump inhibitor risks and recommendations to discontinue: a national survey","volume":"115","author":"Kurlander","year":"2020","journal-title":"Am J Gastroenterol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650852104083X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650852104083X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:50:41Z","timestamp":1762163441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001650852104083X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":92,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S001650852104083X"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2021.12.247","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2021.12.247","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the AGA Institute","name":"copyright","label":"Copyright"}]}}